Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer

• Published in: Radiology. Imaging cancer Vol. 5; no. 2; p. e220022
• Main Authors: Ravi, Harshan, Arias-Lorza, Andres M., Costello, James R., Han, Hyo Sook, Jeong, Daniel K., Klinz, Stephan G., Sachdev, Jasgit C., Korn, Ronald L., Raghunand, Natarajan
• Format: Journal Article
• Language: English
• Published: United States Radiological Society of North America 01.03.2023
• Subjects: Brain Neoplasms - diagnostic imaging; Brain Neoplasms - drug therapy; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Female; Ferrosoferric Oxide; Humans; Irinotecan - therapeutic use; Magnetic Resonance Imaging - methods; Middle Aged; Original Research; MRI; Breast; Tumor Response; Experimental Investigations; Head/Neck; Brain/Brain Stem; MRI Contrast Agent

Purpose To investigate ferumoxytol (FMX)-enhanced MRI as a pretreatment predictor of response to liposomal irinotecan (nal-IRI) for thoracoabdominal and brain metastases in women with metastatic breast cancer (mBC). Materials and Methods In this phase 1 expansion trial (ClinicalTrials.gov identifier...